Perry P. Guaglianone

Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

Stephen K. Williamson, James Moon, Chao Huang et al. · Journal of Clinical Oncology · 2010 · 110 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)

Perry P. Guaglianone, Kenneth K. Chan, Eduardo Delaflor–Weiss et al. · Investigational New Drugs · 1994 · 81 citations

Pharmacy, Pharmacokinetics, Pharmacology +7

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study

Roy S. Herbst, Mary W. Redman, Edward S. Kim et al. · The Lancet Oncology · 2017 · 74 citations · Full text

Medicine, Oncology, Pharmacology +15

A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix

Charles A. Kunos, Wei Deng, Dawn Dawson et al. · International Journal of Gynecological Cancer · 2015 · 65 citations · Full text

Medicine, Oncology, Pharmacology +16

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

Primo N. Lara, Kari Chansky, Angela M. Davies et al. · Journal of Thoracic Oncology · 2006 · 54 citations · Full text

Medicine, Oncology, Pharmacotherapy +9